Literature DB >> 11818435

Inappropriate use of digoxin in older hospitalized heart failure patients.

Ali Ahmed1, Richard M Allman, James F DeLong.   

Abstract

BACKGROUND: Older adults are more likely to suffer from the adverse effects of digoxin. Studies have described the inappropriate use of digoxin in various populations. The objective of this study was to determine the correlates of inappropriate digoxin use in older heart failure patients.
METHODS: We studied older hospitalized heart failure patients with documented left ventricular (LV) function evaluation and electrocardiography. Digoxin use was considered inappropriate if patients had preserved LV systolic function (ejection fraction greater > or =40%) or if they had no atrial fibrillation (AF). We compared baseline patient characteristics by indication for digoxin and tested statistical significance using Pearson's chi-square analysis and Student's t tests. Using logistic regression, we determined the correlates of inappropriate use and initiation of digoxin.
RESULTS: Subjects (N = 603) had a mean age of 79 (+/-7) years; 59% were women, and 18% were African American. A total of 376 patients (62%) were discharged on digoxin, and 223 (37%) had no indication for its use. Half of the patients without an indication for digoxin received the drug. Of 132 patients without an indication and not already on digoxin, 38 (29%) were initiated on it. After adjustment for various patient and care characteristics, prior digoxin use (adjusted odds ratio [OR] 11.47, 95% confidence interval [CI] 5.72-23.02) and pulse > or =100/min (adjusted OR 2.33, 95% CI 1.10-4.94) were associated with inappropriate digoxin use. Pulse > or =100/min was also associated with inappropriate initiation of the drug (adjusted OR 2.95, 95% CI 1.28-6.78).
CONCLUSIONS: Inappropriate use of digoxin was common and was associated with prior use. Tachycardia was associated with inappropriate use and initiation. Electrocardiography and echocardiography should be performed in all older heart failure patients. Digoxin therapy should not be initiated or continued in patients without any evidence of LV systolic dysfunction or chronic AF.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11818435     DOI: 10.1093/gerona/57.2.m138

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  6 in total

Review 1.  Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

2.  Patterns of drug prescription in a geriatric evaluation and management unit as compared with the general medical wards: a randomised study.

Authors:  Ingvild Saltvedt; Olav Spigset; Sabine Ruths; Peter Fayers; Stein Kaasa; Olav Sletvold
Journal:  Eur J Clin Pharmacol       Date:  2005-11-24       Impact factor: 2.953

3.  Effects of medication assessment as part of a comprehensive geriatric assessment on drug use over a 1-year period: a population-based intervention study.

Authors:  Pasi Lampela; Sirpa Hartikainen; Piia Lavikainen; Raimo Sulkava; Risto Huupponen
Journal:  Drugs Aging       Date:  2010-06-01       Impact factor: 3.923

4.  Serum digoxin concentration and outcomes in women with heart failure: A bi-directional effect and a possible effect modification by ejection fraction.

Authors:  Ali Ahmed; Inmaculada B Aban; Michael T Weaver; Wilbert S Aronow; Jerome L Fleg
Journal:  Eur J Heart Fail       Date:  2005-11-28       Impact factor: 15.534

5.  Inappropriate use of digoxin in patients presenting with digoxin toxicity.

Authors:  Mustafa Adem Tatlisu; Kazim Serhan Ozcan; Baris Gungor; Ahmet Zengin; Mehmet Baran Karatas; Zekeriya Nurkalem
Journal:  J Geriatr Cardiol       Date:  2015-03       Impact factor: 3.327

6.  Potentially inappropriate prescribing in Ethiopian geriatric patients hospitalized with cardiovascular disorders using START/STOPP criteria.

Authors:  Tadesse Melaku Abegaz; Eshetie Melese Birru; Gashaw Binega Mekonnen
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.